Hikma Pharmaceuticals PLC (LON: HIK)
London
· Delayed Price · Currency is GBP · Price in GBX1,877.00
+10.00 (0.54%)
Jul 22, 2024, 3:44 PM GMT
Hikma Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
| Net Income | 190 | 190 | 188 | 421 | 431 | 486 | Upgrade
|
| Depreciation & Amortization | 102 | 102 | 93 | 83 | 82 | 73 | Upgrade
|
| Amortization of Goodwill & Intangibles | 88 | 88 | 92 | 86 | 43 | 34 | Upgrade
|
| Depreciation & Amortization, Total | 190 | 190 | 185 | 169 | 125 | 107 | Upgrade
|
| Other Amortization | 8 | 8 | 8 | 11 | 10 | 10 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -6 | 1 | 2 | 3 | Upgrade
|
| Loss (Gain) From Sale of Investments | -2 | -2 | 2 | - | -1 | 2 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | 1 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 61 | 61 | 179 | -35 | -44 | -18 | Upgrade
|
| Stock-Based Compensation | 25 | 25 | 22 | 29 | 27 | 24 | Upgrade
|
| Other Operating Activities | 56 | 56 | 83 | 69 | 122 | -98 | Upgrade
|
| Change in Accounts Receivable | -24 | -24 | 4 | -166 | -47 | 21 | Upgrade
|
| Change in Inventory | -115 | -115 | -102 | 38 | -180 | -25 | Upgrade
|
| Change in Accounts Payable | 88 | 88 | 16 | 14 | 6 | -6 | Upgrade
|
| Change in Other Net Operating Assets | 131 | 131 | -49 | 86 | 13 | -34 | Upgrade
|
| Operating Cash Flow | 608 | 608 | 530 | 638 | 464 | 472 | Upgrade
|
| Operating Cash Flow Growth | 14.72% | 14.72% | -16.93% | 37.50% | -1.69% | 9.77% | Upgrade
|
| Capital Expenditures | -169 | -169 | -138 | -145 | -172 | -119 | Upgrade
|
| Sale of Property, Plant & Equipment | 18 | 18 | 1 | - | - | 2 | Upgrade
|
| Cash Acquisitions | -98 | -98 | -373 | - | - | -8 | Upgrade
|
| Divestitures | - | - | -1 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -35 | -35 | -78 | -84 | -52 | -67 | Upgrade
|
| Investment in Securities | -26 | -26 | -15 | 3 | -3 | 8 | Upgrade
|
| Other Investing Activities | -23 | -23 | -3 | -12 | -56 | 33 | Upgrade
|
| Investing Cash Flow | -333 | -333 | -607 | -238 | -283 | -151 | Upgrade
|
| Short-Term Debt Issued | 437 | 437 | 380 | 383 | 430 | 267 | Upgrade
|
| Long-Term Debt Issued | 778 | 778 | 1,401 | 10 | 1,543 | 19 | Upgrade
|
| Total Debt Issued | 1,215 | 1,215 | 1,781 | 393 | 1,973 | 286 | Upgrade
|
| Short-Term Debt Repaid | -467 | -467 | -363 | -431 | -367 | -273 | Upgrade
|
| Long-Term Debt Repaid | -851 | -851 | -971 | -76 | -1,386 | -23 | Upgrade
|
| Total Debt Repaid | -1,318 | -1,318 | -1,334 | -507 | -1,753 | -296 | Upgrade
|
| Net Debt Issued (Repaid) | -103 | -103 | 447 | -114 | 220 | -10 | Upgrade
|
| Repurchase of Common Stock | - | - | -300 | - | -375 | - | Upgrade
|
| Dividends Paid | -137 | -137 | -125 | -120 | -109 | -97 | Upgrade
|
| Other Financing Activities | -97 | -97 | -80 | -53 | -34 | -48 | Upgrade
|
| Financing Cash Flow | -337 | -337 | -58 | -287 | -298 | -155 | Upgrade
|
| Foreign Exchange Rate Adjustments | -3 | -3 | -21 | -10 | -2 | - | Upgrade
|
| Net Cash Flow | -65 | -65 | -156 | 103 | -119 | 166 | Upgrade
|
| Free Cash Flow | 439 | 439 | 392 | 493 | 292 | 353 | Upgrade
|
| Free Cash Flow Growth | 11.99% | 11.99% | -20.49% | 68.84% | -17.28% | 9.29% | Upgrade
|
| Free Cash Flow Margin | 15.27% | 15.27% | 15.57% | 19.31% | 12.47% | 15.99% | Upgrade
|
| Free Cash Flow Per Share | 1.97 | 1.97 | 1.74 | 2.12 | 1.23 | 1.45 | Upgrade
|
| Cash Interest Paid | 82 | 82 | 68 | 50 | 39 | 44 | Upgrade
|
| Cash Income Tax Paid (Refunded) | 129 | 129 | 55 | 129 | 61 | 108 | Upgrade
|
| Levered Free Cash Flow | 445.25 | 445.25 | 244.38 | 269.75 | 24.88 | 299.25 | Upgrade
|
| Unlevered Free Cash Flow | 490.88 | 490.88 | 281.25 | 296.63 | 50.5 | 321.75 | Upgrade
|
| Change in Net Working Capital | -85 | -85 | 29 | 34 | 225 | -63 | Upgrade
|
Source: S&P Capital IQ. Standard template.